Atlas-incubated Kymera Therapeutics has gotten off a $30 million series A and taken on Pierre Fabre’s R&D head as its new chief. The Cambridge, Massachusetts-based biotech is one of a handful of companies working on targeted protein degradation, which it hopes will help treat a series of diseases that has thus far proven untreatable.
If you find a dimension intereseting, we recommend you pick up one or two facts that you find intriguing and place them into your memory. That way you will have 2nd degree information about the topic if it comes up in conversation.
Accordingly, you can do the same with others as well.